Recombinant luteinizing hormone supplementation in women undergoing in vitro fertilization/ intracytoplasmic sperm injection with gonadotropin releasing hormone antagonist protocol: A systematic review and meta-analysis

Reproductive Biology and Endocrinology

Volumn 12, Issue 1, 2014, Pages

  Xiong, Yujing ^a   Bu, Zhiqin ^a   Dai, Wei ^a   Zhang, Meixiang ^a   Bao, Xiao ^a   Sun, Yingpu ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

Meta analysis; Oral contraceptive pills; Ovarian stimulation; Recombinant FSH; Recombinant LH

Indexed keywords

ESTRADIOL; GONADORELIN ANTAGONIST; PROGESTERONE; RECOMBINANT FOLLITROPIN; RECOMBINANT LUTEINIZING HORMONE; GONADORELIN; LUTEINIZING HORMONE; RECOMBINANT PROTEIN;

ESTRADIOL BLOOD LEVEL; HUMAN; IN VITRO FERTILIZATION; INTRACYTOPLASMIC SPERM INJECTION; META ANALYSIS; OOCYTE RETRIEVAL; OUTCOME ASSESSMENT; OVARY HYPERSTIMULATION; PATIENT SAFETY; PREGNANCY OUTCOME; PREGNANCY RATE; PROGESTERONE BLOOD LEVEL; REVIEW; SYSTEMATIC REVIEW; ANTAGONISTS AND INHIBITORS; DIET SUPPLEMENTATION; FEMALE; FERTILIZATION IN VITRO; GENETICS; PREGNANCY;

DIETARY SUPPLEMENTS; FEMALE; FERTILIZATION IN VITRO; GONADOTROPIN-RELEASING HORMONE; HUMANS; LUTEINIZING HORMONE; PREGNANCY; PREGNANCY OUTCOME; RECOMBINANT PROTEINS; SPERM INJECTIONS, INTRACYTOPLASMIC;

EID: 84964314562     PISSN: None     EISSN: 14777827     Source Type: Journal    
DOI: 10.1186/1477-7827-12-109     Document Type: Review

References (27)

1. Albano C, Smitz J, Camus M, Riethmuller-Winzen H, Van Steirteghem A, Devroey P: Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation. Fertil Steril 1997, 67:917-922.
2. Lindheim SR, Morales AJ: GnRH antagonists followed by a decline in serum estradiol results in adverse outcomes in donor oocyte cycles. Hum Reprod 2003, 18:2048-2051.
3. Mochtar MH, der Veen V, Ziech M, van Wely M: Recombinant Luteinizing Hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles. Cochrane Database Syst Rev 2007, 2:CD005070.
4. Ferraretti AP, Gianaroli L, Magli MC, D'Angelo A, Farfalli V, Montanaro N: Exogenous luteinizing hormone in controlled ovarian hyperstimulation for assisted reproduction techniques. Fertil Steril 2004, 82:1521-1526.
5. Griesinger G, Schultze-Mosgau A, Dafopoulos K, Schroeder A, Schroer A, von Otte S, Hornung D, Diedrich K, Felberbaum R: Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol. Hum Reprod 2005, 20:1200-1206.
6. Sauer MV, Thornton MH 2nd, Schoolcraft W, Frishman GN: Comparative efficacy and safety of cetrorelix with or without mid-cycle recombinant LH and leuprolide acetate for inhibition of premature LH surges in assisted reproduction. Reprod Biomed Online 2004, 9:487-493.
7. Levi-Setti PE, Cavagna M, Bulletti C: Recombinant gonadotrophins associated with GnRH antagonist (cetrorelix) in ovarian stimulation for ICSI: comparison of r-FSH alone and in combination with r-LH. Eur J Obstet Gynecol Reprod Biol 2006, 126:212-216.
8. Lisi F, Rinaldi L, Fishel S, Caserta D, Lisi R, Campbell A: Evaluation of two doses of recombinant luteinizing hormone supplementation in an unselected group of women undergoing follicular stimulation for in vitro fertilization. Fertil Steril 2005, 83:309-315.
9. Matorras R, Prieto B, Exposito A, Mendoza R, Crisol L, Herranz P, Burgues S: Mid-follicular LH supplementation in women aged 35-39 years undergoing ICSI cycles: a randomized controlled study. Reprod Biomed Online 2009, 19:879-887.
10. Baruffi RL, Mauri AL, Petersen CG, Felipe V, Martins AM, Cornicelli J, Cavagna M, Oliveira JB, Franco JG Jr: Recombinant LH supplementation to recombinant FSH during induced ovarian stimulation in the GnRHantagonist protocol: a meta-analysis. Reprod Biomed Online 2007, 14:14-25.
11. Youssef MA, Van der Veen F, Al-Inany HG, Griesinger G, Mochtar MH, van Wely M: Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles. Cochrane Database Syst Rev 2010, 1:CD008046.
12. Wong PC, Qiao J, Ho C, Ramaraju GA, Wiweko B, Takehara Y, Nadkarni PV, Cheng LC, Chen HF, Suwajanakorn S, Vuong TN: Current opinion on use of luteinizing hormone supplementation in assisted reproduction therapy: an Asian perspective. Reprod Biomed Online 2011, 23:81-90.
13. Hill MJ, Levens ED, Levy G, Ryan ME, Csokmay JM, DeCherney AH, Whitcomb BW: The use of recombinant luteinizing hormone in patients undergoing assisted reproductive techniques with advanced reproductive age: a systematic review and meta-analysis. Fertil Steril 2012, 97:1108-1114. e1101.
14. Bosch E, Labarta E, Crespo J, Simon C, Remohi J, Pellicer A: Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: an age-adjusted analysis. Fertil Steril 2011, 95:1031-1036.
15. Konig TE, van der Houwen LE, Overbeek A, Hendriks ML, Beutler-Beemsterboer SN, Kuchenbecker WK, Renckens CN, Bernardus RE, Schats R, Homburg R, Homburg R, Hompes PG, Lambalk CB: Recombinant LH supplementation to a standard GnRH antagonist protocol in women of 35 years or older undergoing IVF/ICSI: a randomized controlled multicentre study. Hum Reprod 2013, 28:2804-2812.
16. Diedrich K, Diedrich C, Santos E, Zoll C, Al-Hasani S, Reissmann T, Krebs D, Klingmuller D: Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation. Hum Reprod 1994, 9:788-791.
17. Olivennes F, Alvarez S, Bouchard P, Fanchin R, Salat-Baroux J, Frydman R: The use of a GnRH antagonist (Cetrorelix) in a single dose protocol in IVF-embryo transfer: a dose finding study of 3 versus 2 mg. Hum Reprod 1998, 13:2411-2414.
18. Damario MA, Barmat L, Liu HC, Davis OK, Rosenwaks Z: Dual suppression with oral contraceptives and gonadotrophin releasing-hormone agonists improves in-vitro fertilization outcome in high responder patients. Hum Reprod 1997, 12:2359-2365.
19. O'Dea L, O'Brien F, Currie K, Hemsey G: Follicular development induced by recombinant luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in anovulatory women with LH and FSH deficiency: evidence of a threshold effect. Curr Med Res Opin 2008, 24:2785-2793.
20. Vaskivuo TE, Tapanainen JS: Apoptosis in the human ovary. Reprod Biomed Online 2003, 6:24-35.
21. Fortune JE, Voss AK: Oxytocin gene expression and action in bovine preovulatory follicles. Regul Pept 1993, 45:257-261.
22. Brown JB: Pituitary control of ovarian function-concepts derived from gonadotrophin therapy. Aust N Z J Obstet Gynaecol 1978, 18:46-54.
23. Loumaye E, Engrand P, Shoham Z, Hillier SG, Baird DT: Clinical evidence for an LH 'ceiling' effect induced by administration of recombinant human LH during the late follicular phase of stimulated cycles in World Health Organization type I and type II anovulation. Hum Reprod 2003, 18:314-322.
24. Filicori M, Cognigni GE, Taraborrelli S, Spettoli D, Ciampaglia W, Tabarelli De Fatis C, Pocognoli P, Cantelli B, Boschi S: Luteinzing hormone activity in menotropins optimizes folliculogenesis and treatment in controlled ovarian stimulation. J Clin Endocrinol Metab 2001, 86:337-343.
25. Rombauts L, Healy D, Norman RJ: A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist-treated patients. Hum Reprod 2006, 21:95-103.
26. Huirne JA, Homburg R, Lambalk CB: Are GnRH antagonists comparable to agonists for use in IVF? Hum Reprod 2007, 22:2805-2813.
27. Adonakis G, Deshpande N, Yates RW, Fleming R: Luteinizing hormone increases estradiol secretion but has no effect on progesterone concentrations in the late follicular phase of in vitro fertilization cycles in women treated with gonadotropin-releasing hormone agonist and follicle-stimulating hormone. Fertil Steril 1998, 69:450-453.